Revance Therapeutics Inc. | Cash Flow
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
258.00
62,917.00
73,476.00
89,270.00
120,587.00
142,568
Depreciation, Depletion & Amortization
1,881.00
2,051.00
1,995.00
1,445.00
1,468.00
1,726
Other Funds
-
1,438.00
993.00
507.00
573.00
13,879
Funds from Operations
37,977.00
44,841.00
58,193.00
62,588.00
101,785.00
126,963
Changes in Working Capital
9,781.00
10,232.00
2,524.00
2,761.00
6,443.00
22,717
Net Operating Cash Flow
47,758.00
55,073.00
55,669.00
59,827.00
95,342.00
104,246
Capital Expenditures
6,477.00
6,975.00
3,328.00
1,670.00
2,525.00
Sale of Fixed Assets & Businesses
-
-
-
2.00
-
Purchase/Sale of Investments
-
-
53,012.00
72,031.00
121,417.00
Net Investing Cash Flow
6,402.00
6,900.00
56,340.00
75,499.00
118,792.00
Issuance/Reduction of Debt, Net
13,327.00
5,794.00
4,581.00
3,541.00
3,636.00
Net Financing Cash Flow
53,991.00
229,091.00
142,592.00
2,642.00
195,944.00
Net Change in Cash
169.00
167,118.00
30,583.00
137,968.00
219,394.00
Free Cash Flow
54,235.00
62,048.00
58,997.00
61,497.00
97,867.00
Net Assets from Acquisitions
-
-
-
1,800.00
100.00
Other Sources
75.00
75.00
-
-
-
Change in Capital Stock
40,664.00
236,323.00
139,004.00
1,406.00
200,153.00
About Revance Therapeutics
View Profile
